Posterior capsule opacification

01OverviewDefinition, clinical context and the essential points that orientate the chapter.

During most cataract operations the surgeon preserves the posterior part of the lens capsule to support the new implant. Residual lens epithelial cells can subsequently proliferate, change their behaviour and alter the transparency of that membrane. Posterior capsule opacification, often abbreviated to PCO, can therefore develop in an eye whose original cataract has already been removed. Describing it as the cataract growing back is misleading: the opacity is in a different retained structure.

The typical history is useful vision after surgery followed by a gradual return of misting, glare or difficulty with low-contrast tasks over months or years. The interval is variable and symptoms do not establish the diagnosis alone. A new spectacle error, tear-film disturbance, macular oedema, age-related macular degeneration, glaucoma or a displaced implant may cause deterioration in the same eye. Some patients have more than one problem, so an obvious cloudy capsule should not end the examination.

Nd:YAG laser uses focused pulses to create a central aperture in the opacified membrane. This allows light to pass through without another cataract extraction. It is generally an outpatient procedure, but remains an intraocular intervention with pressure, inflammatory and retinal risks. The decision to treat depends on symptoms attributable to the capsule, examination findings and anticipated visual benefit, including whether a clearer view is needed to assess or manage posterior segment disease.

Key points

Posterior capsule opacification is a change in the retained lens capsule after cataract surgery.
It usually causes gradual painless misting, glare or reduced contrast after an initial period of improvement.
Confirm that opacity lies in the visual axis and explains the functional complaint before treating.
Mild asymptomatic opacity can be observed; visually significant opacity is usually treated by Nd:YAG capsulotomy.
Laser makes an opening in the capsule while the intraocular lens remains in place.
Assess pressure risk and provide specific advice about retinal and inflammatory symptoms after treatment.

02AetiologyUnderlying causes, associations and risk factors, with why each one matters.

Residual lens epithelial cells

Cells remaining after cataract extraction can migrate across the capsule and produce fibrous tissue or pearl-like collections. The process explains why transparency may deteriorate despite an initially clear, well-positioned implant.

Ocular and procedural context

The response varies with age, inflammation and features of the operation and implant. PCO is especially relevant in younger eyes, but individual timing cannot be predicted from age alone.

03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.

1
Optical scatter
Capsular folds, fibrosis and cell collections scatter incoming light. Symptoms may be dominated by glare or reduced contrast even when high-contrast visual acuity has changed only modestly.
2
Visual axis involvement
Opacity that crosses the pupil's effective optical pathway is more likely to impair vision. Peripheral capsule changes may be visible at slit lamp yet have little functional effect.
3
Laser aperture
Capsulotomy disrupts the opacified membrane with focused laser energy. The central optical pathway opens while the existing intraocular lens usually continues to provide refractive correction in its original position.

04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.

Chronology and previous result

Establish the date and type of surgery, best vision after recovery and onset of deterioration. Ask whether the eye was ever satisfactorily clear. Persistently poor vision from the outset suggests a broader postoperative or pre-existing problem rather than assuming late capsule opacification.

Symptom profile

Ask about misting, glare, reading, contrast and whether symptoms are monocular. Distortion, pain, redness, flashes and a field shadow change the differential and urgency. Compare functional difficulty with the degree and location of capsular change.

Slit-lamp confirmation

After appropriate pupil assessment and dilation, identify fibrosis, folds or pearl-like changes behind the implant. Check that the implant is centred and that the opacity involves the relevant optical axis. Examine the cornea and anterior chamber rather than viewing only the capsule.

Laser suitability

Review glaucoma history, baseline pressure, retinal risk, previous inflammation and possible need for implant revision. Establish whether the patient can sit and maintain fixation at the laser. If symptoms may require IOL exchange, discuss sequencing with the surgeon before opening the capsule.

Red flags requiring action

Flashes with a curtain-like shadow suggest a retinal tear or detachment rather than uncomplicated capsule opacity.
Severe ocular pain, nausea or coloured haloes after laser require prompt pressure assessment.
Progressive redness and reduced vision warrant urgent review for inflammation or another postoperative complication.
New central distortion should prompt assessment of the macula, even when the capsule looks cloudy.

05InvestigationsWhat to request, why it matters and how to interpret it.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
Acuity and refractionFirst step
Why
Quantify visual change and identify an alternative optical correction.
Interpretation and limitations
Compare with the best postoperative record where available. Improved acuity with refraction supports a refractive contribution, although glare from PCO can persist. A technically visible opacity without meaningful visual impairment does not automatically require laser.
02
Slit-lamp and dilated fundus examination
Why
Localise the opacity and assess the rest of the eye.
Interpretation and limitations
PCO lies behind the intraocular lens, distinguishing it from a corneal opacity or an implant surface problem. Evaluate retinal and optic nerve disease when the view permits. Document limitations if dense opacity prevents a reliable assessment.
03
Intraocular pressure measurement
Why
Identify baseline hypertension and plan peri-laser pressure surveillance.
Interpretation and limitations
An eye with glaucoma may tolerate an acute pressure rise poorly. Existing drops, previous pressure responses and laser characteristics inform prophylaxis and follow-up. A normal baseline reading does not rule out a subsequent pressure spike.
04
Macular optical coherence tomography
Why
Investigate distortion or visual loss exceeding the capsule findings.
Interpretation and limitations
Use targeted imaging when macular disease is suspected or prognosis remains uncertain. Retinal fluid or another structural abnormality may change treatment order. Image quality can itself be limited by capsular opacity and should be considered when interpreting a seemingly normal scan.

06Differential diagnosisRealistic alternatives and the features that help distinguish them.

Macular disease

Distortion, a central scotoma or fluid on optical coherence tomography may identify macular oedema or degeneration. A coincidental cloudy capsule does not explain all central visual symptoms.

Refractive or ocular surface change

Defocus and an unstable tear film can cause blur after an otherwise successful operation. Refraction, blinking response and corneal examination help assess these treatable competing explanations.

Implant or retinal complication

A displaced lens may cause monocular double images or an edge in vision. Flashes, new floaters or a field shadow instead require assessment for vitreoretinal disease.

07ManagementImmediate care, first-line treatment, alternatives and escalation.

01AssessConfirm a symptomatic capsular problemFirst stepVision has deteriorated after an initially successful cataract operation.

1Obtain the chronology and screen for pain, acute loss, retinal warning symptoms and central distortion.
2Measure vision, assess refraction and examine the implant, capsule, pressure and fundus.
3Explain whether PCO is the likely main cause, a contributor or an incidental finding, and investigate competing abnormalities.

02TreatPrepare and perform laser capsulotomyCapsule opacity accounts for meaningful visual difficulty or obstructs necessary examination.

1Discuss observation and the expected benefit of opening the capsule, including limits imposed by coexisting disease.
2Explain dilation, topical anaesthesia and the focusing contact lens, together with pressure, inflammation, implant and retinal risks.
3Check systemic medicines and contraindications before selecting pressure prophylaxis; record baseline pressure and the surveillance plan.
4Use the ophthalmic laser service to create an appropriate central opening and document the procedure and immediate plan.

03ReviewRespond to the post-laser courseLaser treatment is complete and the patient is preparing to leave.

1Provide any prescribed anti-inflammatory or pressure treatment with an explicit duration and arrange checks according to ocular risk.
2Warn that short-lived blur or a few floaters can occur, but explain how a sudden shower, flashes or field shadow differs.
3Arrange urgent review for increasing pain, redness or visual loss and reassess the macula if clarity does not recover as expected.

Key medicines and prescribing safety1 treatment · regimens, roles and cautions

Specialist prophylaxis or control of pressure elevation associated with procedures including capsulotomy.

Apraclonidine 1% for peri-laser pressure control

Instil one drop into the treated eye one hour before anterior segment laser surgery and a second drop immediately after completion.

The cited Iopidine 1% product is contraindicated in children, severe or unstable uncontrolled cardiovascular disease, and with monoamine oxidase inhibitors, systemic sympathomimetics or tricyclic antidepressants. Check clonidine or apraclonidine allergy. Monitor relevant cardiovascular, renal or hepatic impairment; use nasolacrimal occlusion and separate other eye drops by at least five minutes. It is not recommended during pregnancy; for a breastfeeding patient, agree an alternative or the SmPC-directed interruption of breastfeeding with the specialist before treatment.

08ComplicationsImportant consequences, why they occur and why they matter clinically.

Functional visual decline

Untreated symptomatic PCO can compromise reading, mobility and other tasks regained after cataract surgery. The clinical burden depends on the fellow eye and the person's visual demands.

Restricted posterior examination

Dense opacity may prevent an adequate view of the retina and optic nerve. Clearing the visual axis can be useful for examination or treatment even when another disorder limits visual acuity.

Treatment-related ocular events

Capsulotomy can cause a transient pressure rise, inflammation or implant pitting. Less frequent complications include macular oedema, retinal detachment and implant instability, each requiring appropriate assessment when symptoms develop.

09Monitoring and follow-upTreatment response, safety checks and longer-term review.

Arrange early pressure assessment when indicated by glaucoma, baseline hypertension, the procedure or the ophthalmologist's protocol, rather than assuming all eyes share the same follow-up need.
Review persistent blurred central vision for residual opacity, a refractive issue or macular oedema; additional laser is not the automatic response to disappointing vision.
Continue the patient's established glaucoma or retinal monitoring and clarify whether existing eye drops should continue alongside any temporary treatment.
Discuss driving only after dilation and blur have resolved and vision meets the relevant requirement; the patient should arrange an alternative journey home.
Reinforce the urgent eye-service contact route and check that the patient can distinguish expected transient symptoms from a new field defect or substantial deterioration.

10Special situationsVariants, exceptions and circumstances that change the usual approach.

An irreversible opening

Laser permanently changes the capsule. When the implant itself may need replacement for refractive intolerance or instability, discuss the sequence with the operating surgeon first because an opened posterior capsule can complicate later surgery.

Acuity and glare can diverge

An eye may achieve a reasonable chart result by concentrating in favourable lighting while suffering troublesome scatter in daily life. Document both the measured result and the functional complaint; treatment should address a credible optical mechanism.

Persistent symptoms need a fresh examination

Clearing the capsule does not treat an epiretinal membrane, optic neuropathy or corneal surface disease. Improvement may reveal pre-existing floaters more clearly as well. Reassess the symptom's nature before concluding that the laser opening is inadequate.

Counselling about recurrence

The natural lens has been removed, so a new natural-lens cataract cannot form in that eye. Occasionally an opening may require further attention or another ocular condition may develop. Explain the anatomy without promising that no future visual problem is possible.

11Common pitfallsFrequent interpretation and management errors.

01
Calling every episode of postoperative blur a secondary cataract without locating the opacity.
02
Performing capsulotomy for a peripheral capsule change that does not explain the patient's symptoms.
03
Using an adult apraclonidine laser regimen in a child or overlooking interacting systemic medicines.
04
Reassuring a patient with a new retinal field shadow that all floaters after laser are harmless.
05
Escalating to repeat laser without checking macular and refractive explanations for persistent visual loss.